Yes, NVO talked about next generation of insulin in great detail. Basically the focus are three directions: ultra long acting (ULA), ultra fast acting (UFA), oral. The most advanced in NVO pipeline is ULA degludec which is in phase III currently. Oral and UFA are in phase I.
It was a great presentation, a must for anyone interested in diabetes/insulin market. I believed and continue to believe anyone investing in pharma/biotech must have large exposure to diabetes market, which is growing, and will continue to grow really fast worldwide.
Thanks jq. I'm off to a bad start in my BIOD position but I think I will do fine as long as Phase 1 data due in 3Q this year is good on at least one of their two UFA insulin candidates. Should presumably be a low hurdle for Phase 1 success. I do expect BIOD is going to have to raise cash sometime soon, presumably after they report Phase 1 data.
Market Data 
Markets 
AI
